A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Summary

The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.

Timeline

Start

2022-03-07

Primary completion

2023-12-29

Completion

2023-12-29

Outcome

Outcome not reported

Stopped: “Study terminated due to lack of efficacy”

Drugs

Indications